Josefsen D, Ous S, Høie J, Stenwig A E, Fosså S D
Departaent of Medical Oncology and Radiotherapy, Norwegian Radium Hospital, Oslo.
Br J Cancer. 1993 Mar;67(3):568-72. doi: 10.1038/bjc.1993.104.
The outcome of salvage treatment was reviewed in 55 patients relapsing during or after their primary chemotherapy for advanced malignant germ cell tumours. Fifty-two patients had been given cisplatin-based chemotherapy as their primary treatment, whereas three patients had received carboplatin-based chemotherapy. The median time to relapse was 2 months (range: 0-96 months) from discontinuation of the primary treatment. Two patients underwent radical surgery only, and one patient had radiotherapy to a brain metastasis as his only curatively intended salvage treatment. Six patients did not receive any treatment for their recurrent malignancy (refusal, terminal condition) except for purely palliative measures. The disease-free survival for the total group was 27% at 5 years. Complete response to primary treatment lasting for > or = 6 months was the only parameter which significantly predicted a favourable outcome (45% 5 year disease-free survival in 12 eligible patients).
对55例晚期恶性生殖细胞肿瘤患者在初次化疗期间或之后复发时的挽救治疗结果进行了回顾。52例患者接受了以顺铂为基础的化疗作为初次治疗,而3例患者接受了以卡铂为基础的化疗。从初次治疗结束到复发的中位时间为2个月(范围:0 - 96个月)。2例患者仅接受了根治性手术,1例患者对脑转移灶进行了放疗,这是其唯一的根治性挽救治疗。6例患者除了采取单纯的姑息措施外,未对复发性恶性肿瘤进行任何治疗(拒绝治疗、终末期情况)。全组患者5年无病生存率为27%。对初次治疗的完全缓解持续≥6个月是唯一显著预测良好预后的参数(12例符合条件的患者5年无病生存率为45%)。